表紙
市場調查報告書
商品編碼
1027868

多形性膠質母細胞瘤 (GBM) - 市場考察,流行病學,市場預測:2030年

Glioblastoma multiforme (GBM)- Market Insight, Epidemiology and Market Forecast -2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 266 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

主要7個國家的多形性膠質母細胞瘤 (GBM)的整體發病數在2020年為29,440件。

本報告提供多形性膠質母細胞瘤 (GBM) 調查分析,以過去·未來的流行病學,美國·歐洲5個國家 (德國,法國,義大利,西班牙,英國) ·日本的市場趨勢為焦點,提供目前治療方法,新藥,市場規模等相關的系統性資訊。

目錄

第1章 主要考察

第2章 多形性膠質母細胞瘤 (GBM) 市場概要

  • 2018年的多形性膠質母細胞瘤 (GBM)的市場佔有率分佈
  • 2030年的多形性膠質母細胞瘤 (GBM)的市場佔有率分佈

第3章 多形性膠質母細胞瘤 (GBM)的摘要整理

第4章 主要活動

第5章 SWOT分析

第6章 疾病的背景和概要:多形性膠質母細胞瘤 (GBM)

  • 簡介
  • 多形性膠質母細胞瘤 (GBM)的分類
  • 神經膠質母細胞瘤的種類
  • 症狀
  • 病理生理學
  • 多形性膠質母細胞瘤 (GBM)的遺傳
  • 分子的分類
  • 多形性膠質母細胞瘤 (GBM)的診斷
  • Nut Shell的神經膠質母細胞瘤

第7章 治療

  • 手術
  • 化療
  • 放射線
  • 其他
  • 由於投藥的症狀的管理

第8章 治療流程

第9章 美國臨床腫瘤學會 (ASCO) 認證的美國放射線腫瘤學會 (ASTRO)對神經膠質母細胞瘤的放射治療相關指南

第10章 美國綜合癌症網路 (NCCN)的神經膠質母細胞瘤相關指南

第11章 成人的神經膠質母細胞瘤:目前管理與未來的方向性相關神經腫瘤學會 (SNO) 和歐洲神經腫瘤學會 (EANO)的共識檢討

第12章 SEOM (Medical Oncology Spanish Society) 神經膠質母細胞瘤的診斷和治療的臨床指南

第13章 流行病學和患者族群

  • 主要調查結果
  • 流行病學手法
  • 與的多形性膠質母細胞瘤 (GBM) 確診的整體發病數主要7個國家

第14章 多形性膠質母細胞瘤 (GBM)的各國流行病學

  • 美國
  • 歐洲5個國家
  • 日本

第15章 認證設施

第16章 患者療程

第17章 上市藥

  • Avastin:Genentech
  • Temodar/Temodal:Merck
  • Delytact:Daiichi Sankyo

第18章 新藥

  • 主要的競爭企業
  • Ofranergene obadenovec (VB-111):VBL Therapeutics
  • Trans Sodium Crocetinate:Diffusion Pharmaceuticals
  • Regorafenib:Bayer
  • Durvalumab (MEDI4736):MedImmune
  • Tasadenoturev (DNX-2401):DNAtrix
  • ONC201:Chimerix
  • Selinexor (KPT-330):Karyopharm Therapeutics
  • VBI-1901:VBI Vaccines
  • Paxalisib (GDC-0084):Kazia Therapeutics
  • AV-多形性膠質母細胞瘤 (GBM) -1:Aivita Biomedical
  • MDNA55:Medicenna Therapeutics
  • VAL-083 (Dianhydrogalactitol):Kintara Therapeutics
  • LAM561 (2-OHOA):Laminar Pharmaceuticals
  • ITI-1000 (pp65 DC Vaccine):Immunomic Therapeutics
  • INO-5401+ INO-9012+ Cemiplimab (REGN2810):Inovio Pharmaceuticals
  • G207:Treovir
  • PVSRIPO:Istari Oncology

第19章 目前治療藥·新藥的可能性

第20章 多形性膠質母細胞瘤 (GBM) :主要7個市場分析

  • 主要調查結果
  • 市場手法
  • 主要7個國家的多形性膠質母細胞瘤 (GBM)的市場規模全體
  • 市場預測
  • 主要市場預測的前提條件
  • 美國的市場規模
  • 歐洲5個國家的市場規模
  • 日本的市場規模

第21章 KOL的見解

第22章 推動市場要素

第23章 市場障礙

第24章 未滿足需求

第25章 市場進入與償付

第26章 附錄

第27章 DelveInsight的服務內容

第28章 免責聲明

第29章 關於DelveInsight

目錄
Product Code: DIMI0289

DelveInsight's 'Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioblastoma Multiforme (GBM) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2018 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2018-2030

Glioblastoma Multiforme (GBM) Disease Understanding and Treatment Algorithm

Glioblastoma Multiforme (GBM) Overview

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.

GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.

Glioma is considered as the general term which is used to describe the primary brain tumors, and it is also classified to their presumed cell of origin accordingly. The classification includes astrocytic tumors (astrocytoma, anaplastic astrocytoma and glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas. Gliomas are classified into grade I TO IV on the basis of malignancy that is determined by the histopathalogical criteria. Although the location of GBM is commonly found in the supratentorial region (frontal, temporal, parietal, and occipital lobes), it is rarely located in the cerebellum part. Investigation of genetic and environmental factors of GBM have been done. Prior radiography, decreased susceptibility to allergy, immune factors and immune genes, as well as some nucleotide polymorphisms detected by genomic analysis are all included in the risk factors of the respective disease. The histological classification and tumor grading is a critical step for GBM diagnosis and prognosis.

GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. From various experimental evidences it is explained that GBM contains a subpopulation of highly tumorigenic cells (GBM stem cells) from which recurrent GBM is thought to derive, and that GBM has the capacity to differentiate into multiple lineages of tumor genesis.

GBMs can be classified into primary and secondary GBMs:

Primary GBM occurs de novo without evidence of a less malignant precursor

Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioblastoma Multiforme (GBM) Diagnosis

A patient with any neurological symptoms will first be given a physical exam that includes neurologic function tests (reflexes, muscle strength, eye and mouth movement, coordination and alertness). If a tumor is suspected, the patient will have imaging tests so that doctors can look into the brain for any abnormality. A neurological exam alone is not sufficient to make a glioblastoma diagnosis, but the results will indicate whether additional testing is needed. If the results of a neurological exam suggest a potential glioblastoma diagnosis, imaging tests may then be used to produce an in-depth picture of the brain. Procedures that can be used for this purpose include:

Neurological Exams

Angiograms

Magnetic resonance imaging (MRI) and computerized Tomography (CT)

Perfusion MRI

MR spectroscopy

Histological Diagnosis

Surgical Biopsy

Glioblastoma Multiforme (GBM) Treatment

Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient's brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispecialty approach can cause several side effects, steroids are often provided as another essential part of glioblastoma treatment, used to help alleviate the side effects of other therapies.

The mainstay of treatment for Glioblastoma is surgery, followed by radiation and chemotherapy. Glioblastoma surgery is performed to achieve a "maximum safe resection," or removing as much of the tumor as possible without causing lasting neurological damage. Glioblastoma surgery options majorly include: Craniotomy , Awake craniotomy, Debulking surgery, Skull base surgery, Visualase and Kyphoplasty. In most cases, surgeons perform a craniotomy, opening the skull to reach the tumor site. This is done frequently with computer-assisted image-guidance and at times using intra-operative mapping techniques to determine the locations of the motor, sensory and speech/language cortex.

Currently, the first- and second-line treatment of GBM is more prevalent throughout the 7MM. The first-line treatment involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for GBM includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).

Glioblastoma Multiforme (GBM) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population According To Primary Site Of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population According To Histologic Classification of Glioblastoma Multiforme (GBM) Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Key Findings

This section provides glimpse of the Glioblastoma Multiforme (GBM) epidemiology in the 7MM.

The total diagnosed incident population of GBM in the 7 major markets was estimated to be 29,440 in 2020. In case of GBM patients in the United States, the diagnosed incident cases were 15,426 in 2020.

The total diagnosed incident cases of GBM patients were maximum in males as compared to females in the 7 MM during the study period of 2018-2030.

In the EU5 countries, the diagnosed incident population of GBM was maximum in Germany with 2,945 cases followed by France with 2,772 cases in 2020. While, Spain accounted for the lowest diagnosed incident population of 1,462 in 2020.

As per Delvelnsight's analysis, Japan had 1,950 diagnosed incident cases of GBM in 2020.

There were 13,884 patients affected with primary GBM and 1,543 with secondary GBM in 2020, in the United States

The maximum number of the diagnosed incident population in the United States, in 2020, was found at the parietal site with 6,201 cases, followed by frontal tumors with 4,505 cases, temporal tumors with 2,391 cases, 1,620 cases of occipital tumors, and 710 cases of unknown and other tumors.

In 2020, the maximum number of the diagnosed incident population according to the histological classification of GBM were conventional GBM type with 14,964 cases while the lowest incident cases were of GC-GBM type with 123 cases, in the United States.

In the United States, the maximum number of GBM patients lie in the age group of 35-64, which accounted for 10,768 cases in 2020. In contrast, the least number of patients lie in the age group of <18, which was 617 in 2020.

Country Wise- Glioblastoma Multiforme (GBM) Epidemiology

The epidemiology segment also provides the Glioblastoma Multiforme (GBM) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Glioblastoma Multiforme (GBM) Drug Chapters

The drug chapter segment of the Glioblastoma Multiforme (GBM) report encloses the detailed analysis of Glioblastoma Multiforme (GBM) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme (GBM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Glioblastoma Multiforme (GBM) Marketed Drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under "Specialty drugs," only to be available through specialty pharmacies (under FDA's Risk Evaluation and Mitigation Strategy (REMS) program).

The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.

Product details in the report…

Temodar/Temodal: Merck

The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.

Product details in the report…

Glioblastoma Multiforme (GBM) Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug is being investigated using VBL's proprietary Vascular Targeting System (VTS) platform Technology to target endothelial cells in the tumor vasculature for cancer therapy. In November 2019, the company stated that an investigational new drug (IND) application from the US FDA. The IND is for a phase II randomized, controlled, clinical trial of VB-111 in recurrent GBM (rGBM) patients undergoing a second surgery. Currently, the trial is in recruiting phase. In March 2021, the company announced initiation of patient dosing in the Phase II trialThe drug has been rewarded Orphan Drug Designation from both the US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with recurrent GBM.

Product details in the report…

Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely re-oxygenates oxygen-deprived tissue. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM. The company holds broad protection of their patent portfolio ranging through 2031 with possible extensions to 2036. In addition, Orphan Designation by the US FDA for the patients with GBM serves as an additional 7 years of exclusivity as well. Additionally, the phase III trial of the drug for newly diagnosed GBM was terminated in July 2021 (business decision on behalf of the sponsor).

Product details in the report…

Regorafenib: Bayer

Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). The EMA has granted Bayer's Regorafenib Orphan Drug Designation for the treatment of glioma, including GBM. The drug is already approved under the brand name Stivarga in more than 90 countries, including the US, countries of the European Union, China and Japan for metastatic colorectal cancer, metastatic gastrointestinal stromal tumors and hepatocellular carcinoma. Currently, the drug is in phase III stage of clinical development for patients with newly diagnosed and recurrent GBM. Besides, the company witnessed positive phase II REGOMA study results in June 2018 for patients with relapsed GBM.

Product details in the report…

Durvalumab (MEDI4736): MedImmune

Durvalumab is an investigational human monoclonal antibody directed against the programmed cell death ligand 1 (PD-L1) protein in development by MedImmune. Signals from PD-L1 help tumors avoid detection by the immune system. The drug has been approved by brand name Imfinzi for several oncology indications. However, in the case of GBM, the drug is being explored in phase II clinical trials.

Product details in the report…

Tasadenoturev (DNX-2401): DNAtrix

Tasadenoturev (DNX-2401), explored by DNAtrix, is oncolytic immunotherapy. Two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently in order to achieve safety and efficacy. The drug has been granted PRIME and Orphan designation by the EMA and Fast Track and Orphan designation by the FDA . In October 2015, Merck and DNAtrix entered into an oncology clinical study collaboration to evaluate DNX-2401 in combination with Keytruda in a phase II study of patients with rGBM.

Product details in the report…

ONC201: Chimerix

A novel therapeutic intervention of Imipridone class is in development by Chimerix, i.e., ONC201, which is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that can penetrate the blood-brain-barrier effectively. The drug engages proven anticancer pathways that lead to apoptosis in cancer cells. The drug is targeting multiple brain cancer indications such as GBM and Diffuse Intrinsic Pontine Gliomas or Diffuse Midline Glioma altogether. It has found been in early results that this drug can kill cancer cells but not normal cells and may be effective in patients with a specific genetic mutation in their tumour: the H3 K27M mutation. The US FDA has awarded Fast-Track designation to ONC201 for the treatment of adults with who have recurred GBM. Currently, the drug is in phase II stage of clinical development for recurrent GBM, H3 K27M-mutant Glioma and Diffuse Midline Glioma. Besides, recently, in November 2019, the company has witnessed positive interim phase II results of ONC201 in patients with recurrent GBM. In November 2020, the company announced that it had received grants from Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation to fund an Expanded Access program for ONC201 in the United States. In January 2020, the National Brain Tumor Society (NBTS) committed to provide more than USD 200,000 funding to support Oncoceutics' phase II clinical trial of ONC201, in a molecular subset of high grade gliomas.

Product details in the report…

Selinexor (KPT-330): Karyopharm Therapeutics

Selinexor (KPT-330) is a first-in-class, oral selective inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. The drug has been approved with a brand name Xpovio for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision (Karyopharm Therapeutics).

Product details in the report…

Paxalisib (GDC-0084): Kazia Therapeutics

Paxalisib (GDC-0084) inhibits the PI3K pathway that is thought to be critical to the development of certain kinds of tumours. The drug is currently involved in five clinical trials examining the drug in a range of forms of brain cancer, including glioblastoma, DIPG and breast cancer brain metastases (BCBM). The drug is distinguished by its ability to cross the blood-brain barrier (BBB), which prevents many drugs from fully affecting brain tissues. Kazia Therapeutics licensed Paxalisib (as GDC-0084) from Genentech in 2016 and is developing it as a potential treatment for glioblastoma in phase II clinical trial.

Product details in the report…

AV-GBM-1: Aivita Biomedical

AV-GBM-1 is a novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumour antigens derived from self-renewing tumour-initiating cells derived from cultured autologous GBM tumour cells, with potential immuno-stimulatory and antineoplastic activities. Upon a series of subcutaneous administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis. Aivita Biomedical is investigating it as a potential treatment for newly diagnosed GBM in a phase II clinical trial.

Product details in the report…

MDNA55: Medicenna Therapeutics

MDNA55 is a novel first in class Interleukin-4 Empowered Cytokine (IL4-EC). This proprietary targeted drug molecule was designed to harness the exceptional specificity and affinity of superkines (engineered cytokines) to selectively deliver cell-killing stimuli to the bulk tumor, tumor microenvironment (TME), and cancer stem cells (CSC) simultaneously. It has been granted both Fast Track and Orphan Drug Status from the FDA as well as Orphan Drug Designation from the EMA for the treatment of rGBM. Medicenna is developing it as a potential treatment for recurrent or progressive GBM and has completed its phase II clinical trial, in October 2019. In October 2020, the company provided an update on the clinical development of MDNA55. Following an End of Phase II Meeting with the FDA, the agency agreed that the company could conduct an open-label hybrid Phase III trial that allows use of a substantial number of subjects (two-thirds) from a matched external control arm to support regulatory approval of MDNA55 for rGBM. The FDA also expressed willingness to consider an interim analysis of the trial if certain criteria are met. Medicenna is currently pursuing a partnership strategy to facilitate MDNA55's further development and commercialization. Additionally, in May 2021, Medicenna's proposed patient population shows a tumor control rate of 81% (26/32) based on modified RANO criteria. According to the company, the published data in clinical cancer research indicated that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma.

Product details in the report…

Glioblastoma Multiforme (GBM) Market Outlook

Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma. Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depending on many factors like the size and location of the tumor; the extent to which the tumor has grown into the surrounding normal brain tissues; and the affected person's age and overall health.

In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.

Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The potential candidates with promising results in late- and mid-phase of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Chimerix), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (GDC-0084; Kazia Therapeutics), AV-GBM-1 (Aivita Biomedical), Regorafenib (Bayer) and others.

Key Findings

This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.

The market size of GBM in the seven major markets was estimated to be USD 1,022.1 Million in 2020.

The United States accounts for the largest market size of GBM throughout the study period of 2018-2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 674 Million in 2020.

Among the EU5 countries, Germany had the highest market size with USD 72.1 Million in 2020, while Spain had the lowest market size with USD 35.8 Million.

The market size of Japan was estimated to be USD 52.6 Million in 2020

The United States Market Outlook

This section provides the total Glioblastoma Multiforme (GBM) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Glioblastoma Multiforme (GBM) market size and market size by therapies in Japan are provided.

Glioblastoma Multiforme (GBM) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme (GBM) market or expected to get launched in the market during the study period 2018-2030. The analysis covers Glioblastoma Multiforme (GBM) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glioblastoma Multiforme (GBM) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Glioblastoma Multiforme (GBM) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Glioblastoma Multiforme (GBM) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of GBM explaining its causes, signs and symptoms, pathogenesis and currently available therapies.

Comprehensive insight has been provided into the GBM epidemiology and treatment.

Additionally, an all-inclusive account of both the current and emerging therapies for GBM are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

A detailed review of GBM market; historical and forecasted is included in the report, covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM GBM market.

Report Highlights:

In the coming years, GBM market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence GBM R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Delvelnsight has analysed type-specific data of GBM according to which there are two main types of Glioblasoma: Primary (de novo) and Secondary Glioblastoma, where the majority of cases ( > 90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.

Diagnosed incidence according to histological classification of GBM tumor was also assessed, which suggests that the conventional GBM type is more prevalent than giant cell GBM (GC-GBM), and gliosarcoma (GS).

In addition, gener-specific incidence of GBM was also assessed. As per the analysis, GBM is more prevalent in males than in females.

The epidemiology segmentation also encompasses diagnosed incident population according to primary site of glioblastoma. As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at parietal site, while minimum number of cases were found in unknown and other sites. This trend is clearly evident across all the 7MM countries for the study period 2018-2030.

The report also encompasses another major segment, i.e., Age-specific Diagnosed Incident Population of GBM, wherein various age groups have been considered, such as <18, 18-34, 35-64, 65-74 and 75+. It has been found that GBM incidence increases with age peaking at 75-84 years and drops after 85 years.

Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of GBM. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Therapeutics, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology and Inovio Pharmaceuticals.

Glioblastoma Multiforme (GBM) Report Insights

Patient Population

Therapeutic Approaches

Glioblastoma Multiforme (GBM) Pipeline Analysis

Glioblastoma Multiforme (GBM) Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Glioblastoma Multiforme (GBM) Report Key Strengths

Ten Years Forecast

7MM Coverage

Glioblastoma Multiforme (GBM) Epidemiology Segmentation

Key Cross Competition

Highly Analyzed Market

Drugs Uptake

Glioblastoma Multiforme (GBM) Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Questions

Market Insights:

What was the Glioblastoma Multiforme (GBM) market share (%) distribution in 2018 and how it would look like in 2030?

What would be the Glioblastoma Multiforme (GBM) total market size as well as market size by therapies across the 7MM during the forecast period (2021-2030)?

What are the key findings pertaining to the market across the 7MM and which country will have the largest Glioblastoma Multiforme (GBM) market size during the forecast period (2021-2030)?

At what CAGR, the Glioblastoma Multiforme (GBM) market is expected to grow at the 7MM level during the forecast period (2021-2030)?

What would be the Glioblastoma Multiforme (GBM) market outlook across the 7MM during the forecast period (2021-2030)?

What would be the Glioblastoma Multiforme (GBM) market growth till 2030 and what will be the resultant market size in the year 2030?

How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis

Table of Contents

1 Key Insights

2 Glioblastoma Multiforme Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of GBM in 2018
  • 2.2 Market Share (%) Distribution of GBM in 2030

3 Executive Summary of Glioblastoma Multiforme (GBM)

4 Key Events

5 SWOT Analysis

6 Disease Background and Overview: Glioblastoma Multiforme (GBM)

  • 6.1 Introduction
  • 6.2 Classification of Glioblastoma Multiforme
  • 6.3 Glioblastoma Types
    • 6.3.1 Astrocytomas
    • 6.3.2 Ependymomas
    • 6.3.3 Oligodendrogliomas
    • 6.3.4 Mixed gliomas
    • 6.3.5 Optic pathway gliomas
  • 6.4 Symptoms
  • 6.5 Pathophysiology
    • 6.5.1 Macroscopic and Histological Features of GBM
    • 6.5.2 Genetic and Molecular Pathogenesis
  • 6.6 Inheritance of Glioblastoma Multiforme
    • 6.6.1 Genetic Variations of Glioblastoma Multiforme
    • 6.6.2 Isocitrate dehydrogenase mutations
    • 6.6.3 O (6)-Methylguanine-DNA methyltransferase promoter methylation
    • 6.6.4 Telomerase reverse transcriptase promoter mutations
    • 6.6.5 Epidermal growth factor receptor aberrations
    • 6.6.6 PTEN alterations
    • 6.6.7 Other novel genetic aberrations
  • 6.7 Molecular Classification
    • 6.7.1 Specific Molecular Biomarkers
  • 6.8 Diagnosis of Glioblastoma Multiforme
    • 6.8.1 Neurological Exams
    • 6.8.2 Angiograms
    • 6.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 6.8.4 Perfusion MRI
    • 6.8.5 MR spectroscopy
    • 6.8.6 Histological Diagnosis
    • 6.8.7 Surgical Biopsy
  • 6.9 Glioblastoma in Nut Shell

7 Treatment

  • 7.1 Surgery
  • 7.2 Chemotherapy
  • 7.3 Radiation
  • 7.4 Others
    • 7.4.1 Targeted therapy
    • 7.4.2 Tumor treatment fields (TTF)
    • 7.4.3 Immunotherapy
  • 7.5 Management of Symptoms with Medication

8 Treatment Algorithm

9 The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10 The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11 Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

  • 11.1 Medical Management and Supportive Care
  • 11.2 Standard Therapy
  • 11.3 Surgical Management
  • 11.4 Radiotherapy Considerations
  • 11.5 Recurrent Glioblastoma Scenario

12 SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13 Epidemiology and Patient Population

  • 13.1 Key Findings
  • 13.2 Epidemiology Methodology
  • 13.3 Total Diagnosed Incident Patient Population of Glioblastoma Multiforme in the 7MM

14 Country-wise Epidemiology of Glioblastoma Multiforme

  • 14.1 United States
    • 14.1.1 Assumptions and Rationale
    • 14.1.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States
    • 14.1.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 14.1.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 14.1.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 14.1.6 Diagnosed Incident Population based on Primary Site of GBM in the United States
    • 14.1.7 Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States
  • 14.2 EU5 Countries
    • 14.2.1 Assumptions and Rationale
    • 14.2.2 Germany
    • 14.2.3 France
    • 14.2.4 Italy
    • 14.2.5 Spain
    • 14.2.6 United Kingdom
  • 14.3 Japan
    • 14.3.1 Assumptions and Rationale
    • 14.3.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan
    • 14.3.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 14.3.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 14.3.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 14.3.6 Diagnosed Incident Population based on Primary Site of GBM in Japan
    • 14.3.7 Diagnosed Incident Population based on Histologic Classification of GBM in Japan

15 Recognized Establishments

16 Patient Journey

17 Marketed Drugs

  • 17.1 Avastin: Genentech
    • 17.1.1 Drug Description
    • 17.1.2 Regulatory Milestones
    • 17.1.3 Other Development Activities
    • 17.1.4 Safety and Efficacy
    • 17.1.5 Product Profile
  • 17.2 Temodar/Temodal: Merck
    • 17.2.1 Drug Description
    • 17.2.2 Regulatory Milestones
    • 17.2.3 Other Development Activities
    • 17.2.4 Safety and Efficacy
    • 17.2.5 Product Profile
  • 17.3 Delytact: Daiichi Sankyo
    • 17.3.1 Product Description
    • 17.3.2 Regulatory Milestones
    • 17.3.3 Other Development Activities
    • 17.3.4 Product Profile

18 Emerging Drugs

  • 18.1 Key Competitors
  • 18.2 Ofranergene obadenovec (VB-111): VBL Therapeutics
    • 18.2.1 Product Description
    • 18.2.2 Clinical Development
    • 18.2.3 Safety and Efficacy
  • 18.3 Trans Sodium Crocetinate: Diffusion Pharmaceuticals
    • 18.3.1 Product Description
    • 18.3.2 Clinical Development
    • 18.3.3 Safety and Efficacy
  • 18.4 Regorafenib: Bayer
    • 18.4.1 Product Description
    • 18.4.2 Clinical Development
    • 18.4.3 Safety and Efficacy
  • 18.5 Durvalumab (MEDI4736): MedImmune
    • 18.5.1 Product Description
    • 18.5.2 Clinical Development
    • 18.5.3 Safety and Efficacy
  • 18.6 Tasadenoturev (DNX-2401): DNAtrix
    • 18.6.1 Product Description
    • 18.6.2 Clinical Development
    • 18.6.3 Safety and Efficacy
  • 18.7 ONC201: Chimerix
    • 18.7.1 Product Description
    • 18.7.2 Clinical Development
    • 18.7.3 Safety and Efficacy
  • 18.8 Selinexor (KPT-330): Karyopharm Therapeutics
    • 18.8.1 Product Description
    • 18.8.2 Clinical Development
    • 18.8.3 Safety and Efficacy
  • 18.9 VBI-1901: VBI Vaccines
    • 18.9.1 Product Description
    • 18.9.2 Clinical Development
    • 18.9.3 Safety and Efficacy
  • 18.1 Paxalisib (GDC-0084): Kazia Therapeutics
    • 18.10.1 Product Description
    • 18.10.2 Clinical Development
    • 18.10.3 Safety and Efficacy
  • 18.11 AV-GBM-1: Aivita Biomedical
    • 18.11.1 Product Description
    • 18.11.2 Clinical Development
    • 18.11.3 Safety and Efficacy
  • 18.12 MDNA55: Medicenna Therapeutics
    • 18.12.1 Product Description
    • 18.12.2 Clinical Development
    • 18.12.3 Safety and Efficacy
  • 18.13 VAL-083 (Dianhydrogalactitol): Kintara Therapeutics
    • 18.13.1 Product Description
    • 18.13.2 Clinical Development
    • 18.13.3 Safety and Efficacy
  • 18.14 LAM561 (2-OHOA): Laminar Pharmaceuticals
    • 18.14.1 Product Description
    • 18.14.2 Clinical Development
    • 18.14.3 Safety and Efficacy
  • 18.15 ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
    • 18.15.1 Product Description
    • 18.15.2 Clinical Development
    • 18.15.3 Safety and Efficacy
  • 18.16 INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
    • 18.16.1 Product Description
    • 18.16.2 Clinical Development
    • 18.16.3 Safety and Efficacy
  • 18.17 G207: Treovir
    • 18.17.1 Product Description
    • 18.17.2 Clinical Development
    • 18.17.3 Safety and Efficacy
  • 18.18 PVSRIPO: Istari Oncology
    • 18.18.1 Product Description
    • 18.18.2 Clinical Development
    • 18.18.3 Safety and Efficacy

19 Potential of Current Therapies and Emerging Therapies

20 Glioblastoma Multiforme: Seven Major Market Analysis

  • 20.1 Key Findings
  • 20.2 Market Methodology
  • 20.3 Total Market Size of Glioblastoma Multiforme in the 7MM
  • 20.4 Market Outlook
  • 20.5 Key Market Forecast Assumptions
  • 20.6 United States Market Size
    • 20.6.1 Total Market size of Glioblastoma Multiforme in the United States
    • 20.6.2 Market Size of Glioblastoma Multiforme by Current Therapies
    • 20.6.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
  • 20.7 EU-5 Market Size
    • 20.7.1 Total Market size of Glioblastoma Multiforme in EU-5
    • 20.7.2 Market Size of Glioblastoma Multiforme by Current Therapies
    • 20.7.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
  • 20.8 Japan Market Size
    • 20.8.1 Total Market size of Glioblastoma Multiforme in Japan
    • 20.8.2 Market Size of Glioblastoma Multiforme by Current Therapies
    • 20.8.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

21 KOL Views

22 Market Drivers

23 Market Barriers

24 Unmet Needs

25 Market Access and Reimbursement

  • 25.1 United States
  • 25.2 Europe
  • 25.3 Japan

26 Appendix

  • 26.1 Bibliography
  • 26.2 Report Methodology

27 DelveInsight Capabilities

28 Disclaimer

29 About DelveInsight

List of Tables

  • Table 1: Summary of GBM, Market, Epidemiology, and Key Events (2018-2030)
  • Table 2: Key Events
  • Table 3: Glioma grading scale
  • Table 4: Major Dysfunctions Associated with Glioblastoma
  • Table 5: Adjuvant Treatment of Glioblastoma based on Age and Karnofsky Performance Status
  • Table 6: Summary of recommendations
  • Table 7: Total Diagnosed Incident Patient Population of Glioblastoma Multiforme in the 7MM (2018-2030)
  • Table 8: Total Diagnosed Incident Population of GBM in the United States (2018-2030)
  • Table 9: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2018-2030)
  • Table 10: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2018-2030)
  • Table 11: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2018-2030)
  • Table 12: Diagnosed Incident Population based on Primary Site of GBM Tumor in the United States (2018-2030)
  • Table 13: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the US (2018-2030)
  • Table 14: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2018-2030)
  • Table 15: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2018-2030)
  • Table 16: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2018-2030)
  • Table 17: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2018-2030)
  • Table 18: Diagnosed Incident Population based on Primary Site of GBM Tumor in Germany (2018-2030)
  • Table 19: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Germany (2018-2030)
  • Table 20: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2018-2030)
  • Table 21: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Table 22: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Table 23: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Table 24: Diagnosed Incident Population based on Primary Site of GBM Tumor in France (2018-2030)
  • Table 25: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in France (2018-2030)
  • Table 26: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2018-2030)
  • Table 27: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Table 28: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Table 29: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Table 30: Diagnosed Incident Population based on Primary Site of GBM Tumor in Italy (2018-2030)
  • Table 31: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Italy (2018-2030)
  • Table 32: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2018-2030)
  • Table 33: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Table 34: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Table 35: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Table 36: Diagnosed Incident Population based on Primary Site of GBM Tumor in Spain (2018-2030)
  • Table 37: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Spain (2018-2030)
  • Table 38: Total Diagnosed Incident Population of Glioblastoma Multiforme in the UK (2018-2030)
  • Table 39: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Table 40: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Table 41: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Table 42: Diagnosed Incident Population based on Primary Site of GBM Tumor in the UK (2018-2030)
  • Table 43: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the UK (2018-2030)
  • Table 44: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2018-2030)
  • Table 45: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Table 46: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Table 47: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Table 48: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2018-2030)
  • Table 49: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Japan (2018-2030)
  • Table 50: Organizations contributing towards GBM
  • Table 51: Comparison of emerging drugs under development
  • Table 52: Comparison of emerging drugs under development
  • Table 53: VB-111, Clinical Trial Description, 2021
  • Table 54: Trans Sodium Crocetinate, Clinical Trial Description, 2021
  • Table 55: Regorafenib, Clinical Trial Description, 2021
  • Table 56: Durvalumab, Clinical Trial Description, 2021
  • Table 57: Tasadenoturev (DNX-2401), Clinical Trial Description, 2021
  • Table 58: ONC201, Clinical Trial Description, 2021
  • Table 59: Selinexor (KPT-330), Clinical Trial Description, 2021
  • Table 60: VBI-1901, Clinical Trial Description, 2021
  • Table 61: Paxalisib (GDC-0084), Clinical Trial Description, 2021
  • Table 62: AV-GBM-1, Clinical Trial Description, 2021
  • Table 63: MDNA55, Clinical Trial Description, 2021
  • Table 64: VAL-083 (Dianhydrogalactitol), Clinical Trial Description, 2021
  • Table 65: 2-OHOA, Clinical Trial Description, 2021
  • Table 66: pp65 DC Vaccine, Clinical Trial Description, 2021
  • Table 67: INO-5401+ INO-9012+ Cemiplimab (REGN2810), Clinical Trial Description, 2021
  • Table 68: G207, Clinical Trial Description, 2021
  • Table 69: PVSRIPO, Clinical Trial Description, 2021
  • Table 70: Total Market Size of Glioblastoma Multiforme in the 7MM, in USD Million (2018-2030)
  • Table 71: Key Market Forecast Assumptions for Regorafenib
  • Table 72: Key Market Forecast Assumptions for VB-111
  • Table 73: Key Market Forecast Assumptions for Durvalumab
  • Table 74: Key Market Forecast Assumptions for DNX-2401 ± Pembrolizumab
  • Table 75: Key Market Forecast Assumptions for ONC201
  • Table 76: Key Market Forecast Assumptions for KPT-330
  • Table 77: Key Market Forecast Assumptions for VBI-1901
  • Table 78: Key Market Forecast Assumptions for Trans Sodium Crocetinate
  • Table 79: Key Market Forecast Assumptions for Paxalisib
  • Table 80: Key Market Forecast Assumptions for AV-GBM-1
  • Table 81: Key Market Forecast Assumptions for VAL-083
  • Table 82: Key Market Forecast Assumptions for ITI-1000
  • Table 83: Key Market Forecast Assumptions for MDNA55
  • Table 84: Key Market Forecast Assumptions for INO-5401+INO-9012 with cemiplimab
  • Table 85: Key Market Forecast Assumptions for G207 ± Radiation
  • Table 86: Key Market Forecast Assumptions for PVSRIPO
  • Table 87: Total Market Size of GBM in the United States, in USD Million (2018-2030)
  • Table 88: Market size of GBM by Current Therapies in the US, in USD Million (2018-2030)
  • Table 89: Market size of GBM by Emerging Therapies in the US, in USD Million (2018-2030)
  • Table 90: EU5 Market Size of GBM in USD Million (2018-2030)
  • Table 91: Market Size of GBM by Current Therapies in EU5, in USD Million (2018-2030)
  • Table 92: Market Size of GBM by therapies in EU5, in USD Million (2018-2030)
  • Table 93: Total Market Size of Glioblastoma Multiforme in Japan, in USD Million (2018-2030)
  • Table 94: Market size of Glioblastoma Multiforme by Current Therapies in Japan, in USD Million (2018-2030)
  • Table 95: Market size of GBM by Emerging Therapies in Japan, in USD Million (2018-2030)

List of Figures

  • Figure 1: Classification Of Glioblastoma
  • Figure 2: Different types of Glioblastoma
  • Figure 3: Generalized transcription pathways related to Glioblastoma disease
  • Figure 4: Up-regulated Genetic Pathways in Glioblastoma
  • Figure 5: Overall pathways of IDH mutations
  • Figure 6: Chemistry of O6-Methylguanine-DNA Methyltransferase (MGMT)
  • Figure 7: Functioning of MicroRNA as a biomarker in Glioblastoma
  • Figure 8: Treatment Algorithm of GBM
  • Figure 9: NCCN Guidelines for treatment of Anaplastic Gliomas/Glioblastoma
  • Figure 10: NCCN Guidelines for treatment of Recurrent Anaplastic Gliomas/Glioblastoma
  • Figure 11: Total Diagnosed Incident Patient Population of GBM in the 7MM (2018-2030)
  • Figure 12: Total Diagnosed Incident Population of GBM in the US (2018-2030)
  • Figure 13: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2018-2030)
  • Figure 14: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2018-2030)
  • Figure 15: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2018-2030)
  • Figure 16: Diagnosed Incident Population based on Primary Site of GBM Tumor in the US (2018-2030)
  • Figure 17: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the US (2018-2030)
  • Figure 18: Total Diagnosed Incident Population of GBM in Germany (2018-2030)
  • Figure 19: Gender-specific Diagnosed Incidence of GBM in Germany (2018-2030)
  • Figure 20: Type-specific Diagnosed Incidence of GBM in Germany (2018-2030)
  • Figure 21: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2018-2030)
  • Figure 22: Diagnosed Incident Population based on Primary Site of GBM Tumor in Germany (2018-2030)
  • Figure 23: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Germany (2018-2030)
  • Figure 24: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2018-2030)
  • Figure 25: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Figure 26: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Figure 27: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2018-2030)
  • Figure 28: Diagnosed Incident Population based on Primary Site of GBM Tumor in France (2018-2030)
  • Figure 29: Diagnosed Incidence based on Histologic Classification of GBM Tumor in France (2018-2030)
  • Figure 30: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2018-2030)
  • Figure 31: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Figure 32: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Figure 33: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2018-2030)
  • Figure 34: Diagnosed Incident Population based on Primary Site of GBM Tumor in Italy (2018-2030)
  • Figure 35: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Italy (2018-2030)
  • Figure 36: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2018-2030)
  • Figure 37: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Figure 38: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Figure 39: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2018-2030)
  • Figure 40: Diagnosed Incident Population based on Primary Site of GBM Tumor in Spain (2018-2030)
  • Figure 41: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Spain (2018-2030)
  • Figure 42: Total Diagnosed Incident Population of Glioblastoma Multiforme in the UK (2018-2030)
  • Figure 43: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Figure 44: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Figure 45: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2018-2030)
  • Figure 46: Diagnosed Incident Population based on Primary Site of GBM Tumor in the UK (2018-2030)
  • Figure 47: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the UK (2018-2030)
  • Figure 48: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2018-2030)
  • Figure 49: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Figure 50: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Figure 51: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2018-2030)
  • Figure 52: Diagnosed Incident Population based on Primary Site of GBM in Japan (2018-2030)
  • Figure 53: Diagnosed Incident Population based on Histologic Classification of GBM in Japan (2018-2030)
  • Figure 54: Total Market Size of Glioblastoma Multiforme in the 7MM, USD Million (2018-2030)
  • Figure 55: Total Market Size of GBM in the United States, USD Million (2018-2030)
  • Figure 56: Market size of GBM by Current Therapies in the US, USD Million (2018-2030)
  • Figure 57: Market size of GBM by Emerging Therapies in the US, USD Million (2018-2030)
  • Figure 58: Market Size of GBM in EU5, USD Million (2018-2030)
  • Figure 59: Market size of GBM by Current Therapies in EU-5, USD Million (2018-2030)
  • Figure 60: Market size of GBM by Emerging Therapies in EU-5, USD Million (2018-2030)
  • Figure 61: Total Market Size of Glioblastoma Multiforme in Japan, USD Million (2018-2030)
  • Figure 62: Market size of GBM by Current Therapies in Japan, USD Million (2018-2030)
  • Figure 63:Market size of GBM by Emerging Therapies in Japan, USD Million (2018-2030)